Vertex Pharmaceuticals Incorporated (VRTX)
Last Price$484.20.8%
Market Cap$124.7B
Intrinsic value score
6/10
Good
Intrinsic value
$349.8
DCF value - $501.2
Relative value - $198.4
Overvalued
27.8%
LTM P/E
(232.8x)
Peer set median 6.2x
Discount rate
7.5%
VRTX Intrinsic value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
VRTX Historical Intrinsic Value
Crunching data... Almost there!
VRTX vs Peer Set: Intrinsic Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for VRTX
DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate
FAQ
What is Vertex Pharmaceuticals Incorporated intrinsic value?
As of Feb 21, 2025, Vertex Pharmaceuticals Incorporated Intrinsic Value is $349.8. This suggests it may be overvalued by 27.8% compared to its current price of around $484.2.
What is Vertex Pharmaceuticals Incorporated DCF (discounted cash flow) valuation?
As of Feb 21, 2025, Vertex Pharmaceuticals Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at $499.8. This suggests it may be overvalued by 3.2% to its current price of around $484.2, using a discount rate of 7.5% and terminal growth rate of 3.0%.
Is Vertex Pharmaceuticals Incorporated overvalued or undervalued?
Vertex Pharmaceuticals Incorporated is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $349.8, compared to a market price of around $484.2. This suggests a potential overvaluation of 27.8%.